[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349798-105":59,"doc-detail-349798-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","premenopausal-serum-midkine-levels-and-risk-of-estrogen-receptor-positive-breast-cancer-a-prospective-nested-casecontrol-study","Premenopausal serum midkine levels and risk of estrogen receptor-positive breast cancer - a prospective, nested case–control study","","Midkine is a heparin-binding growth factor overexpressed in many malignancies, including breast cancer, but its value as a predictive biomarker for cancer risk in healthy premenopausal women is unclear. A prospective, nested case–control analysis within the NYU Women’s Health Study measured baseline serum midkine in matched cases and controls. Elevated midkine showed an inverse, marginally significant association with later ER-positive breast cancer. Higher baseline levels corresponded to lower long-term risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/premenopausal-serum-midkine-levels-and-risk-of-estrogen-receptor-positive-breast-cancer-a-prospective-nested-casecontrol-study/349798/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/premenopausal-serum-midkine-levels-and-risk-of-estrogen-receptor-positive-breast-cancer-a-prospective-nested-casecontrol-study/349798.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is midkine and why is it relevant to breast cancer risk?","Question",{"text":112,"@type":113},"Midkine is a heparin-binding growth factor overexpressed in many cancers, including breast cancer. The study evaluates whether circulating serum midkine levels can predict future ER-positive breast cancer risk in healthy premenopausal women.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the nested case–control study conducted?",{"text":117,"@type":113},"The analysis used the NYU Women’s Health Study cohort. Serum midkine was measured in baseline samples from 249 women who later developed ER-positive breast cancer and 249 matched controls, using conditional logistic regression to estimate odds ratios.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about serum midkine levels and ER-positive breast cancer?",{"text":121,"@type":113},"Higher circulating midkine levels were associated with a marginally statistically significant lower risk of ER-positive breast cancer. Compared with the lowest quartile, the highest quartile showed an OR of 0.55, and a doubling in midkine corresponded to an OR of 0.66.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349798,1790879077,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Yan et al. Breast Cancer Research (2026) 28:35 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02210-7](https://doi.org/10.1186/s13058-025-02210-7)  \nRESEARCH Open Access  \nPremenopausal serum midkine levels and risk  of estrogen receptor positive breast cancer: a prospective, nested case–control study  \nPengze Yan1,2,3†, Fen Wu4†, Yelena Afanasyeva4, Alan Arslan4, Karen Koenig4, Anne Zeleniuch-Jacquotte4, Yu Chen4* and Kornelia Polyak 1,2,3*  \nAbstract  \nBackground Midkine is a heparin-binding growth factor that is overexpressed in most human malignancies, including breast cancer. While elevated midkine levels have been associated with tumor progression and aging, its role as a predictive biomarker for breast cancer risk in healthy individuals remains unclear. We previously showed that higher midkine expression in estrogen receptor-positive (ER +) breast cancer in younger (\u003C 55) women is associated with shorter disease-free survival. We investigated whether serum midkine levels in premenopausal women are associated with subsequent risk of ER + breast cancer.  \nMethods We conducted a prospective, nested case–control study within the New York University Women’s Health Study (NYUWHS) . Serum midkine levels were measured in baseline blood samples from 249 premenopausal women who developed ER + breast cancer more than 10 years after blood collection and 249 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) across quartilesand continuous midkine levels, adjusting for key breast cancer risk factors.  \nResults Higher circulating midkine levels were associated with a marginally statistically significant lower risk of ER + breast cancer. Compared to the lowest quartile, women in the highest quartile had an OR of 0.55 (95% CI:  \n0.30–0. 99; P for trend = 0 . 10) . A doubling in midkine was associated with a 34% reduction in risk (OR = 0 . 66; 95% CI:  \n0.42–1. 02) . The inverse association was generally consistent across subgroups.  \nConclusion These findings suggest that higher baseline serum midkine levels in premenopausal women are associated with a reduced long-term risk of ER + breast cancer. This challenges prior assumptions about midkine’s uniformly pro-tumorigenic role and suggests it may be a context-dependent biomarker in breast cancer development.  \nKeywords Breast cancer, Midkine, Nested case–control study, Estrogen receptor-positive, NYUWHS, Serum  \n†Pengze Yan and Fen Wu have contributed equally to this work.  \n*Correspondence:  \nYu Chen [Yu.Chen@nyulangone.org](Yu.Chen@nyulangone.org)[ ](Yu.Chen@nyulangone.org)Kornelia Polyak [kornelia_polyak@dfci.harvard.edu](kornelia_polyak@dfci.harvard.edu)  \n1Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA 2Harvard Medical School, Boston, MA, USA  \n3Brigham and Women’s Hospital, Boston, MA, USA  \n4New York University Grossman School of Medicine, 180 Madison Ave, New York 10016, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://cr","cbCaigBtNLcrNItA","https://ap.wps.com/l/cbCaigBtNLcrNItA","pdf",1046712,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is midkine and why is it relevant to breast cancer risk?\",\"answer\":\"Midkine is a heparin-binding growth factor overexpressed in many cancers, including breast cancer. The study evaluates whether circulating serum midkine levels can predict future ER-positive breast cancer risk in healthy premenopausal women.\"},{\"question\":\"How was the nested case–control study conducted?\",\"answer\":\"The analysis used the NYU Women’s Health Study cohort. Serum midkine was measured in baseline samples from 249 women who later developed ER-positive breast cancer and 249 matched controls, using conditional logistic regression to estimate odds ratios.\"},{\"question\":\"What did the study find about serum midkine levels and ER-positive breast cancer?\",\"answer\":\"Higher circulating midkine levels were associated with a marginally statistically significant lower risk of ER-positive breast cancer. Compared with the lowest quartile, the highest quartile showed an OR of 0.55, and a doubling in midkine corresponded to an OR of 0.66.\"}]","Premenopausal serum midkine levels and risk of estrogen receptor-positive breast cancer - a prospective, nested case–control study | PDF",1790085639,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69ae845ee1108edf865f698a795bdeb3.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be0150c421ce93ae5d51c9f312df42ec.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38ede4b51cbf79a8f36b7d30579af62c.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a860b87259c0d84c8472bd4aea214f79.webp",980,1306]